PT1545609E - Anticorpos dirigidos contra apolipoprote?na b oxidada - Google Patents

Anticorpos dirigidos contra apolipoprote?na b oxidada Download PDF

Info

Publication number
PT1545609E
PT1545609E PT03748843T PT03748843T PT1545609E PT 1545609 E PT1545609 E PT 1545609E PT 03748843 T PT03748843 T PT 03748843T PT 03748843 T PT03748843 T PT 03748843T PT 1545609 E PT1545609 E PT 1545609E
Authority
PT
Portugal
Prior art keywords
directed against
antibodies directed
apolipoprotein
passive immunization
against oxidised
Prior art date
Application number
PT03748843T
Other languages
English (en)
Portuguese (pt)
Inventor
Jan Nilsson
Roland Carlsson
Jenny Bengtsson
Leif Strandberg
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202959A external-priority patent/SE0202959D0/xx
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of PT1545609E publication Critical patent/PT1545609E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT03748843T 2002-10-04 2003-10-06 Anticorpos dirigidos contra apolipoprote?na b oxidada PT1545609E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202959A SE0202959D0 (sv) 2002-10-04 2002-10-04 Peptide-Base passive immunization therapy for treatment of atherosclerosis
SE0302312A SE0302312D0 (sv) 2002-10-04 2003-08-27 Peptide-based passive immunization therapy for treatment of atherosclerosis
PCT/SE2003/001469 WO2004030698A1 (en) 2002-10-04 2003-09-22 Peptide-based passive immunization therapy for treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
PT1545609E true PT1545609E (pt) 2011-05-11

Family

ID=28677712

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03748843T PT1545609E (pt) 2002-10-04 2003-10-06 Anticorpos dirigidos contra apolipoprote?na b oxidada

Country Status (19)

Country Link
US (6) US7468183B2 (https=)
EP (3) EP2359848A1 (https=)
JP (5) JP2006506450A (https=)
CN (3) CN102380097A (https=)
AT (1) ATE498407T1 (https=)
AU (2) AU2003263712A1 (https=)
BR (1) BR0315042A (https=)
CY (1) CY1112229T1 (https=)
DE (1) DE60336068D1 (https=)
DK (1) DK1545609T3 (https=)
EE (1) EE200500012A (https=)
ES (1) ES2387423T3 (https=)
PL (1) PL376964A1 (https=)
PT (1) PT1545609E (https=)
RU (2) RU2322260C2 (https=)
SE (1) SE0302312D0 (https=)
SI (1) SI1545609T1 (https=)
TW (2) TW200835517A (https=)
WO (1) WO2004030698A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
UA100255C2 (uk) * 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
US20110207917A1 (en) * 2009-02-09 2011-08-25 Patrys Limited Sam-6 variants, target and methods of use
US8609605B2 (en) 2009-03-17 2013-12-17 Cardiovax, Llc Immunomodulatory methods for treatment of atherosclerosis via inhibition of CD4+ T cell response to APOB100
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
KR20120111724A (ko) * 2009-08-28 2012-10-10 제넨테크, 인크. 항-산화된 ｌｄｌ 항체를 이용한 치료 방법
JP2013510586A (ja) 2009-11-14 2013-03-28 チュウ、カン−ユウ アテローム性動脈硬化を治療及び／又は予防するための免疫調節方法及びシステム
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
HRP20180936T1 (hr) * 2012-06-21 2018-12-14 Indiana University Research And Technology Corporation Analozi glukagona koji pokazuju aktivnost prema receptoru za gip
EP3463416A1 (en) 2016-05-31 2019-04-10 CardioVax, LLC Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN110950952A (zh) * 2019-12-17 2020-04-03 东莞市东阳光生物药研发有限公司 制备抗体的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) * 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5678548A (en) 1995-07-20 1997-10-21 The United States Of America As Represented By The Department Of Health And Human Services System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance
CN1206421A (zh) * 1995-11-01 1999-01-27 科斯药品公司 载脂蛋白e2和阿尔采默氏病的治疗
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9620153D0 (en) 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
CZ299874B6 (cs) * 1997-08-12 2008-12-17 Leadd B. V. Zpusob urcení transformacní schopnosti cinidel, zpusob urcení predispozice bunky, zpusob zjištení genové mutace, použití nukleové kyseliny kódující apoptin a diagnostická testovací souprava
US6156315A (en) 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
WO2000002920A1 (en) 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
ATE506615T1 (de) * 1999-10-26 2011-05-15 Univ California Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
WO2001064008A2 (en) * 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) * 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
JP4159300B2 (ja) 2001-07-05 2008-10-01 株式会社リコー 画像定着装置及び画像形成装置

Also Published As

Publication number Publication date
AU2009201260A1 (en) 2009-04-23
CN102319429A (zh) 2012-01-18
ES2387423T3 (es) 2012-09-21
EE200500012A (et) 2005-08-15
JP2010104374A (ja) 2010-05-13
DE60336068D1 (de) 2011-03-31
EP1545609A2 (en) 2005-06-29
CN102380097A (zh) 2012-03-21
RU2005113235A (ru) 2006-01-20
CN102172400A (zh) 2011-09-07
TW200418504A (en) 2004-10-01
AU2003263712A1 (en) 2004-04-23
US8114966B2 (en) 2012-02-14
US7601353B2 (en) 2009-10-13
CY1112229T1 (el) 2015-12-09
RU2322260C2 (ru) 2008-04-20
BR0315042A (pt) 2005-08-23
EP1545609B1 (en) 2011-02-16
US20080075716A1 (en) 2008-03-27
TWI299666B (en) 2008-08-11
SI1545609T1 (sl) 2011-05-31
TW200835517A (en) 2008-09-01
JP2006506450A (ja) 2006-02-23
US20070098723A1 (en) 2007-05-03
SE0302312D0 (sv) 2003-08-27
US20090155258A1 (en) 2009-06-18
PL376964A1 (pl) 2006-01-09
US20040202653A1 (en) 2004-10-14
RU2007140978A (ru) 2009-05-10
US20120070426A1 (en) 2012-03-22
US20080008702A1 (en) 2008-01-10
AU2009201260B2 (en) 2011-07-28
US7468183B2 (en) 2008-12-23
WO2004030698A1 (en) 2004-04-15
DK1545609T3 (da) 2011-05-02
HK1087018A1 (en) 2006-10-06
EP2359848A1 (en) 2011-08-24
ATE498407T1 (de) 2011-03-15
JP2010222378A (ja) 2010-10-07
JP2010136721A (ja) 2010-06-24
US7521046B2 (en) 2009-04-21
EP2361633A1 (en) 2011-08-31
JP2010104375A (ja) 2010-05-13

Similar Documents

Publication Publication Date Title
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
DE60236646D1 (de) Anti-VEGF-2 Antikörper
EA200500497A3 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИ-IFN-γ НЕЙТРАЛИЗУЮЩИЕ АНТИТЕЛА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ ПУТЕЙ IFN-γ
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
CY1112425T1 (el) Αντισωματα αντι-ngf για την θεραπευτικη αγωγη διαφορων διαταραχων
WO2002083849A3 (en) Vascular endothelial growth factor 2
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
FR12C0004I1 (https=)
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
FI20011403L (fi) Menetelmä ja koostumukset vatsan sairauksien hoitoon
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
EA200601386A1 (ru) ИММУНОГЛОБУЛИНЫ ПРОТИВ АНТИГЕНА EpCAM
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
DE60042489D1 (de) Impfstoff gegen neisseria infektion
DE50205438D1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
EP1566386A4 (en) GENUS IN CONNECTION WITH HAIR LOSS, THE POLYPEPTIDE ENCODED THEREON AND APPLICATIONS THEREOF
UA33294A (uk) Спосіб реабілітації хворих після металоостеосинтезу внутрішньосуглобових переломів.